Avizafone Stats & Data

- Avizafone is a water‑soluble peptide prodrug that is rapidly converted in vivo to diazepam; therefore, most safety/effect considerations mirror diazepam rather than avizafone itself. Formal human IM PK data are limited in open sources.

- Because avizafone (MW ≈ 430.18 g/mol) converts to diazepam (MW ≈ 284.74 g/mol), the theoretical maximum mass yield is ≈0.66 mg diazepam per 1 mg avizafone if conversion were complete; practical oral potency may be lower due to variable enzymatic conversion. This explains frequent anecdotal reports of avizafone feeling weaker per milligram than diazepam. Inference from molecular weights; see citations.

- Diazepam and its active metabolite N‑desmethyldiazepam have long half‑lives (roughly 20–50 h and up to ~100 h, respectively), so accumulation with repeated doses is likely; residual impairment can persist into the next day. Avoid driving or operating machinery for at least 24 h after significant dosing and longer if sedated.

- Strong CYP2C19/CYP3A4 inhibitors (e.g., fluvoxamine, ketoconazole, omeprazole, macrolides, grapefruit) can raise diazepam levels and prolong sedation; enzyme inducers (e.g., carbamazepine, rifampin, St. John’s wort) can blunt effects. Genetic CYP2C19 poor metabolizers may experience exaggerated or prolonged responses.

- Combining with opioids, alcohol, GHB/GBL, or other sedatives markedly increases the risk of respiratory depression, overdose, and death. This risk is documented across epidemiologic and clinical sources; avoid such combinations.

- Intended clinical use of avizafone was to enable parenteral delivery of diazepam without organic solvents. If someone chooses to inject despite risks, avoid improvised propylene glycol/ethanol solutions (propylene glycol toxicity is a known hazard with parenteral benzos), use only sterile water or bacteriostatic water, sterile technique, new needles, and rotate sites; seek medical attention for signs of infection (redness, warmth, pain, fever).

- Intranasal avizafone appears inconsistently effective in user reports, likely because efficient conversion occurs systemically; oral or medically administered IM routes produce more reliable diazepam exposure.

- Powder is often reported as hygroscopic and sticky; if using volumetric dosing, prepare small volumes, label clearly, refrigerate short‑term, and discard if cloudiness, precipitate, or odor develops. Household preservation practices cannot guarantee sterility; contamination risk rises with time.

- Tolerance develops with frequent use; limit use days per week and avoid consecutive‑day dosing. If physically dependent, seek a clinician‑supervised diazepam taper rather than abrupt cessation to reduce seizure/withdrawal risk.

- Mixed stimulant–depressant use can mask intoxication; once the stimulant wears off, excessive benzodiazepine effect may unmask, increasing overdose risk.